About: Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances
Creator	Ghaebi, Mahnaz Osali, Abdolreza Roshangar, Leila Ahmadi, \| Hamed Valizadeh, \|
Source	Medline; PMC
abstract	The ongoing outbreak of the recently emerged 2019 novel coronavirus (nCoV), which has seriously threatened global health security, is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with high morbidity and mortality. Despite the burden of the disease worldwide, still, no licensed vaccine or any specific drug against 2019‐nCoV is available. Data from several countries show that few repurposed drugs using existing antiviral drugs have not (so far) been satisfactory and more recently were proven to be even highly toxic. These findings underline an urgent need for preventative and therapeutic interventions designed to target specific aspects of 2019‐nCoV. Again the major factor in this urgency is that the process of data acquisition by physical experiment is time‐consuming and expensive to obtain. Scientific simulations and more in‐depth data analysis permit to validate or refute drug repurposing opportunities predicted via target similarity profiling to speed up the development of a new more effective anti‐2019‐nCoV therapy especially where in vitro and/or in vivo data are not yet available. In addition, several research programs are being developed, aiming at the exploration of vaccines to prevent and treat the 2019‐nCoV. Computational‐based technology has given us the tools to explore and identify potentially effective drug and/or vaccine candidates which can effectively shorten the time and reduce the operating cost. The aim of the present review is to address the available information on molecular determinants in disease pathobiology modules and define the computational approaches employed in systematic drug repositioning and vaccine development settings for SARS‐CoV‐2.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1002/jcp.29771
bibo:pmid	32557648
has license	no-cc
sha1sum (hex)	a4c9ee331f28f675204b5c51c4677bf46e59db07
schema:url	https://doi.org/10.1002/jcp.29771
resource representing a document's title	Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances
has PubMed Central identifier	PMC7323389
has PubMed identifier	32557648
schema:publication	J Cell Physiol
resource representing a document's body	covid:a4c9ee331f28f675204b5c51c4677bf46e59db07#body_text
is schema:about of	named entity 'repurposed drugs' named entity 'exploration' named entity 'effectively' named entity 'process' named entity 'drug' named entity 'target' named entity 'tools' named entity 'aspects' named entity 'licensed' named entity 'SARS-CoV-2' named entity 'emerged' named entity 'permit' named entity 'vaccine' named entity 'profiling' named entity 'time' named entity 'urgency' named entity '2019-nCoV' named entity 'data' named entity 'prevent' named entity 'data acquisition' named entity '2019-nCoV' named entity '2019-nCoV' named entity 'antiviral drugs' named entity 'physical experiment' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'Vaccine' named entity 'operating cost' named entity 'aiming' named entity 'RNA viruses' named entity 'COVID' named entity 'immunopathology' named entity 'COVID' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'immune response' named entity 'Th1' named entity 'coronavirus' named entity 'Lucchese' named entity 'scientific research' named entity 'SARS-CoV-2' named entity 'epitopes' named entity 'lungs' named entity 'genus' named entity 'ACE2' named entity 'disease burden' named entity 'delivery routes' named entity 'gene' named entity 'endemic' named entity 'kDa' named entity 'pathogenic viruses' named entity 'protein' named entity 'protein' named entity 'RNA-dependent RNA polymerase' named entity 'single-stranded RNA' named entity 'nucleocapsid' named entity 'human population' named entity 'SARS-CoV-2' named entity 'endothelium' named entity 'nucleocapsid' named entity 'immunization' named entity 'antibody response' named entity 'high-affinity' named entity 'epitopes' named entity 'epitope' named entity 'peptides' named entity 'SARS-CoV' named entity 'vaccine against COVID-19' named entity 'HCoV-NL63' named entity 'vaccine' named entity 'viral evolution' named entity 'IgG antibodies' named entity 'Drosten' named entity 'vaccination' named entity 'nucleocapsid' named entity 'viral genomes' named entity 'protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software